...
首页> 外文期刊>Biochimica et biophysica acta. Molecular basis of disease: BBA >Prognostic molecular markers in pediatric liver disease - Are there any?
【24h】

Prognostic molecular markers in pediatric liver disease - Are there any?

机译:儿科肝病的预后分子标记 - 有什么吗?

获取原文
获取原文并翻译 | 示例
           

摘要

Pediatric liver disease (PLD) is a major cause of severe morbidity and prolonged hospitalizations in children. Stratifying patients in terms of prognosis remains challenging. The limited knowledge about molecular mechanisms causing and accompanying PLD remains the main obstacle in a search for reliable prognostic biomarkers. A systematic search of MEDLINE via PubMed and Embase via OVID was conducted on studies published between August 2007 and August 2017. Molecular markers with a prognostic potential in terms of survival, need for liver transplantation or disease progression/regression were selected. In general, identified studies were single center smaller case-control studies or case series with a low level of evidence and a high risk of bias. Only 23 studies comprising 898 patients could be included, mostly focusing on biliary atresia, non-alcoholic fatty liver disease, viral hepatitis, and LT; and markers related to morphogenesis and fibrosis. Furthermore, molecular markers in metabolic pathways and inflammation shown to be relevant, however requiring further validation. Hence, further biological and clinical studies are needed to gain greater molecular insight into PLD.
机译:儿科肝病(PLD)是儿童严重发病率和长期住院的主要原因。分层患者在预后仍然具有挑战性。导致和伴随PLD的分子机制有限的知识仍然是寻求可靠预后生物标志物的主要障碍。通过PubMed和Embase通过HEDID系统搜索MEDLINE,在2007年8月至2017年8月期间发表的研究进行了研究。分子标志物在存活方面具有预后潜力,选择需要肝移植或疾病进展/回归。通常,确定的研究是单中心较小的案例控制研究或案例系列,证据水平低,偏差风险很高。只有23项患有898名患者的研究,主要是专注于胆道休息,非酒精性脂肪肝疾病,病毒性肝炎,和LT;和与形态发生和纤维化有关的标记。此外,代谢途径和炎症中的分子标记显示为相关,但需要进一步验证。因此,需要进一步的生物学和临床研究来增加对PLD的更大的分子洞察力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号